Semaglutide vs SLU-PP-332
FDA Approved vs Emerging
monitor Researched · 90% Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
Molecular Data
Semaglutide SLU-PP-332
Weight 4,113.64 Da 290.32 Da
Half-life ~7 days (168 hours) Under investigation (no human PK data)
Chain 31 amino acids Non-peptide small molecule
Type GLP-1 receptor agonist Synthetic ERR agonist
Key Benefits
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
SLU-PP-332
01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction
Dosing Protocols
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
SLU-PP-332
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) / Research only - not approved for human use
Standard Metabolic Protocol 50 mg/kg (animal dosing) Twice daily
Acute Exercise Enhancement 50 mg/kg (animal dosing) Single dose 1 hour pre-exercise
Extended Treatment 50 mg/kg (animal dosing) Twice daily for 4-8 weeks
Side Effects
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
SLU-PP-332
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Contraindications
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Research Evidence
Semaglutide SLU-PP-332
Status FDA Approved Emerging
References 9 studies 4 studies
Latest 2025-06 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.